Drug Profile


Alternative Names: R-101933

Latest Information Update: 20 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.; Jules Bordet Institute
  • Class Benzazepines; Quinolines
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Breast cancer; Solid tumours

Most Recent Events

  • 20 Sep 2006 No development reported - Phase-II for Breast cancer in Europe (IV-infusion)
  • 20 Jul 2006 No development reported - Phase-I for Solid tumours in Belgium (IV-infusion)
  • 27 Jun 2000 A study has been added to the adverse events, pharmacokinetics, drug interactions and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top